Physician profile
Daljit Kaur
NPI 1477224277
$586.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.59 · 2023: $530 · 2024: $32.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $91.78 | 2023 | Libtayo |
| Merck Sharp & Dohme LLC | $87.48 | 2023 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $75.00 | 2023 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $56.41 | 2023 | Vpriv |
| Astrazeneca Pharmaceuticals Lp | $45.72 | 2023 | Lynparza |
| Janssen Biotech, INC. | $34.70 | 2023 | Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $32.42 | 2024 | |
| Genzyme Corporation | $30.00 | 2023 | |
| Sumitomo Pharma America, INC. | $28.50 | 2023 | Orgovyx |
| Puma Biotechnology, INC. | $25.04 | 2023 | |
| Eisai INC. | $23.59 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $22.14 | 2023 | Imbruvica |
| Amgen INC. | $17.03 | 2023 | Lumakras |
| Beigene USA, INC. | $16.24 | 2023 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.